Dr Lenz on the Prognostic Value of HER2 Expression in mCRC
Heinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.
Heinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.
James Allison, Ph.D., is co-leader of the Immunotherapy Moon Shot platform at MD Anderson Cancer Center. He was recently named one of TIME’s 100 most…
A real-world study found adding a PD-L1 inhibitor to cabozantinib offered no significant survival advantage for patients with metastatic kidney cancer who had already received…
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Nature Reviews Disease Primers – This Primer by Weller and colleagues summarizes the epidemiology, pathophysiology, diagnosis and treatment of glioma in both adults and children.
Prostate cancer is the most common type of cancer in men and is currently the second-leading cause of death in men in the U.S. In…
Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.
Monica Avila, MD, talks about what inspires her, what challenges her and what exciting projects she’s working on
Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EMBT Meeting, focusing on ongoing efforts within the GVHD treatment arena.
Lung and Bronchus Cancer statistics
Jacob Sands, MD, shares updated data from the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan versus docetaxel in non-squamous non-small cell lung cancer recently presented…